SC 0191
Alternative Names: SC-0191Latest Information Update: 18 Apr 2024
At a glance
- Originator Biocity Biopharmaceutics
- Class Antineoplastics; Small molecules
- Mechanism of Action WEE1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Ovarian cancer
- Phase I Solid tumours
Most Recent Events
- 12 Apr 2024 Tianshu Liu plans a phase II trial for Colorectal cancer (Metastatic disease, Second-line or greater therapy) in China (NCT06363552)
- 01 Dec 2023 Phase-I clinical trials in Solid tumours in China (PO), prior to December 2023 (Biocity Biopharmaceutics pipeline, December 2023)
- 01 Dec 2023 Phase-I/II clinical trials in Ovarian cancer (Late-stage disease, Second-line therapy or greater, Combination therapy) in China (PO), prior to December 2023 (Biocity Biopharmaceutics pipeline, December 2023) (NCT06055348)